Peces R, Urra J M
Service of Nephrology, Hospital Alarcos, Ciudad Real, Spain.
Nephrol Dial Transplant. 1995;10(6):871-3.
The influence of calcium-channel blocker treatment on in-vitro TNF alpha production by peripheral blood mononuclear cells (PBMC) from renal transplant recipients treated with cyclosporin was studied.
We compared spontaneous and OKT3-induced TNF alpha production of 12 renal transplant recipients treated with calcium-channel blocker therapy with that of 18 renal transplant recipients who were never treated with a calcium antagonist.
The two groups were similar with regards to age, time after transplantation, dosage of immunosuppressive drugs, and blood cyclosporin levels. Spontaneous (481 +/- 161 versus 319 +/- 74 pg/ml, n.s.) and OKT3-induced (745 +/- 182 versus 632 +/- 112 pg/ml, n.s.) TNF alpha production were similar in both groups.
The results indicate that in cyclosporin-treated renal transplant recipients calcium-channel blockers do not affect TNF alpha production.
研究钙通道阻滞剂治疗对接受环孢素治疗的肾移植受者外周血单个核细胞（PBMC）体外肿瘤坏死因子α（TNFα）产生的影响。
我们比较了12例接受钙通道阻滞剂治疗的肾移植受者与18例从未接受过钙拮抗剂治疗的肾移植受者的自发及OKT3诱导的TNFα产生情况。
两组在年龄、移植后时间、免疫抑制药物剂量及血中环孢素水平方面相似。两组的自发TNFα产生（分别为481±161与319±74 pg/ml，无显著差异）及OKT3诱导的TNFα产生（分别为745±182与632±112 pg/ml，无显著差异）相似。
结果表明，在接受环孢素治疗的肾移植受者中，钙通道阻滞剂不影响TNFα的产生。
